drugset / Trial / NCT00219752
Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The aim of this phase II trial is asses the tolerability and the effectiveness of imatinib in patients with chronic myelogenous leukemia in chronic phase with age more than 70, diagnosis of cml is being performed within 1 year. Quality of life will be carefully assessed.
Timeline
- Start
- 2002-05
- Primary completion
- —
- Completion
- 2007-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 400 mg | — |